Structure-Function Analysis of the Mcl-1 Protein Identifies a Novel Senescence-regulating Domain
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Specifically, a unique loop domain within MCL1 regulates its phenotypic response to DNA damage [25].”
From MCL1 nuclear translocation induces chemoresistance in colorectal carcinoma (2022) · cites this paper as [25]
In the citing paper
“emerging data highlight additional functions related to autophagy, mitochondrial respiration [22, 23], and DNA damage [24–26], which may also contribute to chemoresistance and cancer progression.”
From MCL1 nuclear translocation induces chemoresistance in colorectal carcinoma (2022) · cites this paper as [25]
In the citing paper
“We previously reported that MCL1-mediated chemoresistance requires a novel loop domain containing residues 194–207 [25].”
From MCL1 nuclear translocation induces chemoresistance in colorectal carcinoma (2022) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Senescence in tumours: evidence from mice and humans
Collado, M., & Serrano, M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2772 · Cited by 1,124 · cited 3×
“These data are also consistent with studies showing a better prognosis associated with high levels of senescence observed in multiple forms of cancer before and after treatment.(20).”
BackgroundResultA Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy
Schmitt, C. A., Fridman, J. S., Yang, M., Lee, S., Baranov, E., Hoffman, R. M., & Lowe, S. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00734-1 · Cited by 1,050
Disruption of p53 in human cancer cells alters the responses to therapeutic agents.
Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6863 · Cited by 1,044
Structural biology of the Bcl-2 family of proteins
Petros, A. M., Olejniczak, E. T., & Fesik, S. W. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2003.08.012 · Cited by 745 · cited 1×
“Characterizing these prosurvival proteins is a common canonical binding groove that sequesters and neutralizes proapoptotic proteins (3) and, therefore, is presumed to be essential for mediating tumor development and progression and resistance to therapeutic intervention (4) Consequently, continuous efforts are focuse…”
BackgroundHallmarks of senescence in carcinogenesis and cancer therapy
Shay, J. W., & Roninson, I. B. (2004) · Oncogene · doi:10.1038/sj.onc.1207518 · Cited by 502 · cited 1×
“The HCT116 CRC cell line was the first cell line to have somatic deletions in senescence-related proteins and, therefore, is used widely as a model for CIS (22, 47, 48).”
MethodThe MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer
Stewart, M. L., Fire, E., Keating, A. E., & Walensky, L. D. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.391 · Cited by 418
Domina, A. M., Vrana, J. A., Gregory, M. A., Hann, S. R., & Craig, R. W. (2004) · Oncogene · doi:10.1038/sj.onc.1207692 · Cited by 327 · cited 1×
“of Mcl-1 are two major and two minor proline, glutamic acid, serine, and threonine (PEST) sequences that are targets of phosphorylation and contribute to the relatively short half-life of Mcl-1 (2–3 h) (28).”
BackgroundHong, Y., Downey, T., Eu, K. W., Koh, P. K., & Cheah, P. Y. (2010) · Clinical & Experimental Metastasis · doi:10.1007/s10585-010-9305-4 · Cited by 319 · cited 1×
“7, Aii and Aiii, illustrate both at the protein (representative of multiple immunohistochemistry samples) and mRNA levels (using Oncomine database software with the Hong dataset (34) (Fig.”
MethodOncogenic protein interfaces: small molecules, big challenges
Nero, T. L., Morton, C. J., Holien, J. K., Wielens, J., & Parker, M. W. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3690 · Cited by 312 · cited 1×
“Although this form of therapy may have direct clinical applicability, it can also be used to design other effective small-molecule inhibitors, a strategy already having clinical success in some cancers (46).”
BackgroundUnleashing the power of inhibitors of oncogenic kinases through BH3 mimetics
Cragg, M. S., Harris, C., Strasser, A., & Scott, C. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2615 · Cited by 185 · cited 1×
“Encouraging results using small molecule inhibitors in both murine studies and human clinical trials have identified antiapoptotic Bcl-2 family members, especially Mcl-1, as attractive targets for cancer therapy (37).”
BackgroundCellular senescence predicts treatment outcome in metastasised colorectal cancer
Haugstetter, A. M., Loddenkemper, C., Lenze, D., Gröne, J., Standfuß, C., Petersen, I., Dörken, B., & Schmitt, C. A. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605784 · Cited by 117
Cancer cell senescence: a new frontier in drug development
Cairney, C. J., Bilsland, A. E., Evans, T. R. J., Roffey, J., Bennett, D. C., Narita, M., Torrance, C. J., & Keith, W. N. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.01.019 · Cited by 50 · cited 1×
“As a result, there are now a number of drugs in clinical cancer trials whose primary purpose is the induction of senescence (21).”
Background
Research works printed but not linked: 36
- Beroukhim, 2010, The landscape of somatic copy-number alteration across human cancers, Nature, 463, 899, 10.1038/nature08822 · DOI · Paper page
- Placzek, 2010, A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy, Cell Death Dis, 1, e40, 10.1038/cddis.2010.18 · DOI · Paper page
- Elkholi, 2011, The role of BH3-only proteins in tumor cell development, signaling, and treatment, Genes Cancer, 2, 523, 10.1177/1947601911417177 · DOI · Paper page
- Juin, 2013, Decoding and unlocking the BCL-2 dependency of cancer cells, Nat. Rev. Cancer, 13, 455, 10.1038/nrc3538 · DOI · Paper page
- Baggstrom, 2011, A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer, J. Thorac. Oncol, 6, 1757, 10.1097/JTO.0b013e31822e2941 · DOI · Paper page
- Ng, 2014, Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma, Clin. Adv. Hematol. Oncol, 12, 224
- van Delft, 2006, The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized, Cancer Cell, 10, 389, 10.1016/j.ccr.2006.08.027 · DOI · Paper page
- Placzek, 2011, Identification of a novel Mcl-1 protein binding motif, J. Biol. Chem, 286, 39829, 10.1074/jbc.M111.305326 · DOI · Paper page
- Bolesta, 2012, Inhibition of Mcl-1 promotes senescence in cancer cells: implications for preventing tumor growth and chemotherapy resistance, Mol. Cell. Biol, 32, 1879, 10.1128/MCB.06214-11 · DOI · Paper page
- Stewart, 2010, Ubiquitin-independent degradation of antiapoptotic MCL-1, Mol. Cell. Biol, 30, 3099, 10.1128/MCB.01266-09 · DOI
- Wei, 2012, Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency, Cancer Cell, 21, 547, 10.1016/j.ccr.2012.02.028 · DOI · Paper page
- Petros, 2014, Fragment-based discovery of potent inhibitors of the anti-apoptotic MCL-1 protein, Bioorg. Med. Chem. Lett, 24, 1484, 10.1016/j.bmcl.2014.02.010 · DOI
- Pfannenstiel, 2012, Raiding the pharmacy: genomic screening identifies known chemotherapies as negative regulators of MCL1, Genome Med, 4, 53, 10.1186/gm352 · DOI
- Zhong, 2005, Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis, Cell, 121, 1085, 10.1016/j.cell.2005.06.009 · DOI · Paper page
- Thomas, 2010, Mcl-1: the molecular regulation of protein function, FEBS Lett, 584, 2981, 10.1016/j.febslet.2010.05.061 · DOI · Paper page
- Germain, 2007, The N terminus of the anti-apoptotic BCL-2 homologue MCL-1 regulates its localization and function, J. Biol. Chem, 282, 32233, 10.1074/jbc.M706408200 · DOI · Paper page
- Varadarajan, 2013, Evaluation and critical assessment of putative MCL-1 inhibitors, Cell Death Differ, 20, 1475, 10.1038/cdd.2013.79 · DOI
- Bunz, 1998, Requirement for p53 and p21 to sustain G2 arrest after DNA damage, Science, 282, 1497, 10.1126/science.282.5393.1497 · DOI · Paper page
- Grabow, 2014, MCL-1 but not BCL-XL is critical for the development and sustained expansion of thymic lymphoma in p53-deficient mice, Blood, 124, 3939, 10.1182/blood-2014-09-601567 · DOI · Paper page
- Demelash, 2012, Achaete-scute homologue-1 (ASH1) stimulates migration of lung cancer cells through Cdk5/p35 pathway, Mol. Biol. Cell, 23, 2856, 10.1091/mbc.e10-12-1010 · DOI
- Dimri, 1995, A biomarker that identifies senescent human cells in culture and in aging skin in vivo, Proc. Natl. Acad. Sci. U.S.A, 92, 9363, 10.1073/pnas.92.20.9363 · DOI · Paper page
- Perciavalle, 2012, Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration, Nat. Cell Biol, 14, 575, 10.1038/ncb2488 · DOI · Paper page
- De Biasio, 2007, N-terminal truncation of antiapoptotic MCL1, but not G2/M-induced phosphorylation, is associated with stabilization and abundant expression in tumor cells, J. Biol. Chem, 282, 23919, 10.1074/jbc.M700938200 · DOI
- Han, 2004, Degradation of Mcl-1 by granzyme B: implications for Bim-mediated mitochondrial apoptotic events, J. Biol. Chem, 279, 22020, 10.1074/jbc.M313234200 · DOI
- Fire, 2010, Mcl-1-Bim complexes accommodate surprising point mutations via minor structural changes, Protein Sci, 19, 507, 10.1002/pro.329 · DOI · Paper page
- Warr, 2011, Mitochondrion-dependent N-terminal processing of outer membrane Mcl-1 protein removes an essential Mule/Lasu1 protein-binding site, J. Biol. Chem, 286, 25098, 10.1074/jbc.M111.218321 · DOI
- Liu, 2011, A CC' loop decoy peptide blocks the interaction between Act1 and IL-17RA to attenuate IL-17- and IL-25-induced inflammation, Sci. Signal, 4, ra72, 10.1126/scisignal.2001843 · DOI · Paper page
- Staub, 2009, An expression module of WIPF1-coexpressed genes identifies patients with favorable prognosis in three tumor types, J. Mol. Med, 87, 633, 10.1007/s00109-009-0467-y · DOI
- Belmar, 2015, Small molecule Mcl-1 inhibitors for the treatment of cancer, Pharmacol. Ther, 145, 76, 10.1016/j.pharmthera.2014.08.003 · DOI · Paper page
- Song, 2011, The BH3 mimetic ABT-737 induces cancer cell senescence, Cancer Res, 71, 506, 10.1158/0008-5472.CAN-10-1977 · DOI
- Haferkamp, 2013, Vemurafenib induces senescence features in melanoma cells, J. Invest. Dermatol, 133, 1601, 10.1038/jid.2013.6 · DOI
- Giuliano, 2011, Advances in melanoma senescence and potential clinical application, Pigment Cell Melanoma Res, 24, 295, 10.1111/j.1755-148X.2010.00820.x · DOI
- Billard, 2013, BH3 mimetics: status of the field and new developments, Mol. Cancer Ther, 12, 1691, 10.1158/1535-7163.MCT-13-0058 · DOI · Paper page
- Blagosklonny, 2001, Unwinding the loop of Bcl-2 phosphorylation, Leukemia, 15, 869, 10.1038/sj.leu.2402134 · DOI
- Chang, 1997, Identification of a novel regulatory domain in Bcl-X(L) and Bcl-2, EMBO J, 16, 968, 10.1093/emboj/16.5.968 · DOI · Paper page
- Muchmore, 1996, X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death, Nature, 381, 335, 10.1038/381335a0 · DOI · Paper page
Cited by
Basu, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107943 · Cited by 171
Targeting MCL-1 protein to treat cancer: opportunities and challenges
Tantawy, S. I., Timofeeva, N., Sarkar, A., & Gandhi, V. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1226289 · Cited by 90
MCL1 nuclear translocation induces chemoresistance in colorectal carcinoma
Fu, D., Pfannenstiel, L., Demelash, A., Phoon, Y. P., Mayell, C., Cabrera, C., Liu, C., Zhao, J., Dermawan, J., Patil, D., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-021-04334-y · Cited by 29
Self-citation
Metadata
- Authors
- Demelash, A., Pfannenstiel, L. W., Tannenbaum, C. S., Li, X., Kalady, M. F., DeVecchio, J., & Gastman, B. R.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2015-09
- Volume
- 290
- Issue
- 36
- Pages
- 21962-21975
- ISSN
- 0021-9258
- Cited by
- 27
- References
- 12
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 1833 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.